Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuronetics Inc (STIM)
NASDAQ:STIM
Holding STIM?
Track your performance easily
STIM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.66 - $5.07
Previous Close$0.75
Volume830.54K
Average Volume (3M)409.70K
Market Cap
$22.73M
Enterprise Value$42.75M
Total Cash (Recent Filing)$42.60M
Total Debt (Recent Filing)$62.62M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Nov 05, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding30,295,465
10 Day Avg. Volume534,132
30 Day Avg. Volume409,703
Standard Deviation0.35
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.17
Price to Sales (P/S)0.32
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.59
Enterprise Value/Gross Profit0.83
Enterprise Value/Ebitda-1.82
Forecast
1Y Price Target
$3.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Neuronetics News
PremiumCompany Announcements
Neuronetics Moves to Acquire Greenbrook in Stock Deal
PremiumCompany Announcements
Neuronetics Outlines Greenbrook Acquisition Prospects and Risks
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe company secured an FDA clearance for adjunct treatment for adolescent patients, which expands its TAM by ~35% and should contribute materially in 2025.
Merger BenefitsThe merger is expected to bring $15 million of annualized cost savings, largely due to marketing spend optimization.
Revenue GrowthSTIM's Treatment revenue continues to grow double digits and the company has stayed steadfast in its cost management and operating leverage initiatives with expectations for positive cash flow in 4Q24.
Bears Say
Capital SalesCapital sales were negatively impacted by longer-than-expected average time for customers to secure credit.
Cybersecurity BreachDisruption from the Change Healthcare cybersecurity breach continued to impact the company's capital and treatment session sales.
Revenue GuidanceSoft 2Q24 revenue guidance was fairly below Street expectations.
---
Ownership Overview
1063.07% Insiders
978.44% Mutual Funds
3774.72% Other Institutional Investors
3749.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STIM FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was $0.66 and its highest was $5.07 in the past 12 months.
What is Neuronetics Inc’s market cap?
Currently, no data Available
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is Nov 05, 2024 which is in 28 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on Aug 12, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.269 by -$0.061.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -$0.23.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 30,301,104 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.269. Following the earnings report the stock price went down -58.427%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Among the largest hedge funds holding Neuronetics Inc’s share is First Eagle Investment Management LLC. It holds Neuronetics Inc’s shares valued at 2M.
---
Neuronetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (300.00% Upside)
$3.00 (300.00% Upside)
Hedge Fund Trend
Increased
By 301.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $168.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.02%
12-Months-Change
Fundamentals
Return on Equity
-100.13%
Trailing 12-Months
Asset Growth
-3.56%
Trailing 12-Months
Company Description
Neuronetics Inc
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
---
STIM Company Deck
---
STIM Earnings Call
Q2 2024
0:00 / 0:00
---
STIM Stock 12 Month Forecast
Average Price Target
$3.00
▲(300.00% Upside)
Technical Analysis
Best Analysts Covering STIM
1 Year
1 Year Success Rate
4/17 ratings generated profit
1 Year Average Return
-38.29%
reiterated a buy rating 2 months ago
Copying William Plovanic's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -38.29% per trade.
---